Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial

AIMS/INTRODUCTION: Insulin degludec/insulin aspart (IDegAsp) is a soluble combination of insulin degludec (70%) and insulin aspart (30%). The present exploratory trial investigated the safety of switching unit‐to‐unit from twice‐daily basal or pre‐mix insulin to twice‐daily IDegAsp in Japanese patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Onishi, Yukiko, Yamada, Kenichi, Zacho, Jeppe, Ekelund, Jan, Iwamoto, Yasuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334300/
https://www.ncbi.nlm.nih.gov/pubmed/27560769
http://dx.doi.org/10.1111/jdi.12569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5334300/
https://www.ncbi.nlm.nih.gov/pubmed/27560769
http://dx.doi.org/10.1111/jdi.12569

Ejemplares similares